Maxim Sees Major Upside In These Biotech Stocks

In a recent report, analysts at Maxim Group discussed the biotechnology sector and gave their outlook for five names in the space. Here's a rundown of what they had to say.

Athersys, Inc. ATHX

Analysts believe that Athersys may have found a "sweet spot" for stroke treatment timing, as data from a phase II trial of MultiStem treatment one to two days after a stroke event is expected soon. Maxim has a Buy rating on Athersys and a $9.00 target for the stock.

Cytori Therapeutics Inc CYTX

Cytori recently announced an emphasis on cost-cutting initiatives as it moves forward with its adipose-derives regenerative cell (ADRC) treatment trials. Analysts see big potential for the company in the scleroderma treatment space. Maxim has a Buy rating on Cytori and a $7.00 price target for the stock.

Ocata Therapeutics Inc OCAT

Analysts like the fundamental science and technology that Ocata brings to the table, but they are concerned about the near-term funding risk the company faces after it failed to close a $50 million funding raise in late 2014. Maxim has a Hold rating on Ocata.

OncoSec Medical Inc ONCS

Analysts like the results that OncoSec has seen so far in using up regulation of IL12 to drive cytotoxic T cells to attack tumors. Maxim has a Buy rating on OncoSec and a $3.00 target for the stock.

Tekmira Pharmaceuticals Corp TKMR

Maxim believes that the company is undervalued following its merger with OnCor. Maxim's Buy rating and $27.00 price target for Tekmira is based on an average of sum-of-the-parts, free cash flow and discounted cash flow valuation models.